Erin Longbrake is a Neurology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6 Devine St
Suite 2b
North Haven, CT 064732195
Telephone
203-287-6100Registry record last updated 29 Jun 2016.
Clinical trials
- Intestinal Immunity in Neurologic Disease
Sponsor: Yale University
- Identifying and Characterizing Preclinical MS
Sponsor: Yale University
- Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients
Sponsor: Yale University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20257 payments
- Alexion Pharmaceuticals, Inc.Program year20252 payments
- GENZYME CORPORATIONProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
66.2%Gabapentinoids21.1%Gabapentin72%Pregabalin28%Part D<11 patientsPotassium Channel Blocker18.1%Dalfampridine Er100%Part D<11 patients+ 5 more classes in this area
Musculoskeletal
21.5%gamma-Aminobutyric Acid-ergic Agonist16.5%Baclofen100%Part D≥18 patientsCentral alpha-2 Adrenergic Agonist5.1%Tizanidine Hcl100%Part D<11 patientsCancer & immunology
12.2%CD20-directed Cytolytic Antibody7.2%Kesimpta Pen100%Part D<11 patientsOther immunostimulants5.1%Glatiramer Acetate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2019–2023 per NIH RePORTER. The latest:
- Interactions between Gut Microbiome and B-Cell Depletion in Multiple Sclerosis
Yale University
FY2023$196,020K23NS107624 - Interactions between Gut Microbiome and B-Cell Depletion in Multiple Sclerosis
Yale University
FY2022$196,020K23NS107624 - Interactions between Gut Microbiome and B-Cell Depletion in Multiple Sclerosis
Yale University
FY2021$196,019K23NS107624
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”